Status:
COMPLETED
FGF-23 and PTH in Hemodialysis Patients
Lead Sponsor:
Medical University of Vienna
Conditions:
Chronic Kidney Disease Requiring Chronic Dialysis
Eligibility:
All Genders
18-100 years
Brief Summary
In this pilot study the investigator will examine the levels of fibroblast growth factor (FGF-23) and parathyroid hormone (PTH) levels during hemodialysis therapy in 30 patients and assess the correla...
Detailed Description
Background: The development of sHPT in hemodialysis patients is a common complication which induces an increase in calcification and atherosclerosis. Elevated FGF-23 levels are already found in early ...
Eligibility Criteria
Inclusion
- \>18 years
- hemodialysis three times a week
Exclusion
- Subject is currently enrolled or not yet completed at least 30 days since ending other investigational device or drug trial(s), or is receiving other investigational agent(s)
- Pregnancy
- Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with the study procedures
Key Trial Info
Start Date :
January 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04350944
Start Date
January 14 2020
End Date
August 31 2020
Last Update
September 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090